- Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration2023 | Publication without faculty affiliation
- Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study2015 | Publication without faculty affiliation
- Brolucizumab - A New Player In The Field Of Anti-VEGF Therapy Of Neovascular Age-Related Macular Degeneration. A Review2022 | First Faculty of Medicine
- Intravitreous Bevacizumab (Avastin) in neovascular age related macular degeneration (pilot study) +1Publication without faculty affiliation
- Research Report University Hospital for clinical assessment CFRB002A2405Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. BAY 86-5321/16598Publication without faculty affiliation
- Effects of Treatment Change in Patients with Neovascular age-related Macular Degeneration; Results from the Czech National Registry2012 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry2012 | First Faculty of Medicine
- Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial2021 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Asymmetric response to ranibizumab in mixed choroidal neovascularization in a neovascular age-related macular degeneration diagnosed on OCT angiography - case report2021 | Third Faculty of Medicine
- Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial2023 | Third Faculty of Medicine, Central Library of Charles University
- Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial2023 | Third Faculty of Medicine, Central Library of Charles University
- Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes2023 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, Central Library of Charles University
- Response to Aflibercept Therapy in Three Types of Choroidal Neovascular Membrane in Neovascular Age-Related Macular Degeneration: Real-Life Evidence in the Czech Republic2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Incidence of adverse events after loading phase of the brolucizumab therapy of neovascular AMD: Real-life evidence in the Czech Republic2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, Central Library of Charles University
- Two-year results of a combined regimen of aflibercept treatment in three types of choroidal neovascular membrane in the wet form of age-related macular degeneration: Real-life evidence in the Czech Republic2021 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. RTH258-C002Publication without faculty affiliation
- Stereotactic radiotherapy for wet age-related macular degeneration (INTREPID): influence of baseline characteristics on clinical response2015 | Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: CFRB002A2405Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: OPH1002Publication without faculty affiliation